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ABSTRACT
Personalized medicine is the science and practice of customizing medical screening and treatment
plans for an individual based on his or her genomic profile. Breast cancer is one of the first disease
areas to serve as an example of this approach, where most patients have experienced its benefits
through the use of genetic tests that provide decision support for health care workers regarding the
likely effectiveness of specific drugs and, more broadly, the urgency of particular treatment options
(for example, chemoprevention versus prophylactic surgery).
Little is known about the diffusion of such personalized approaches to medical practice, particularly
the factors shaping the adoption of genetic tests. While numerous medical diffusion studies have
been published over the past few decades, most were univariate analyses and did not consider the
unique aspects of genetic testing versus drugs. Moreover, they mainly focused on the characteristics
and behaviors of physicians, patients, product manufacturers, and social networks, and did not
explore the role of potentially important third parties like professional medical societies and patient
groups (e.g. disease foundations and patient advocacy organizations).
The aim of this thesis was to analyze the relationship between seven attributes of four breast cancer
genetic tests and clinical adoption to show that standard diffusion frameworks can be enhanced
through previously unstudied dimensions when evaluating personalized medicine-related innova-
tions. We identified four variables that correlated with clinical adoption: 1) regulatory status, 2)
inclusion in practice guidelines by professional societies, 3) explicit endorsement by patient groups,
and 4) implicit endorsement by patient groups. Our findings indicate that a key overlooked element
in the current literature (and potentially overlooked by the firms creating these tests) is the role
of patient groups in the diffusion of novel genetic tests, in addition to endorsement from medical
professional societies. These findings may add value to strategic decisions made by company ex-
ecutives, investors, payers, health care providers, and patients as they are presented with novel
products and development opportunities in the era of personalized medicine.
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Technological innovations, new medical discoveries, and changing paradigms for the delivery of
clinical care have paved the way for the advent of personalized medicine - an approach to disease
prevention and treatment tailored to an individual based on his or her genetic profile [1]. Per-
sonalized medicine strategies hold the promise of dramatically decreasing the chances of adverse
side effects during drug therapy, and, more fundamentally, lowering the overall costs of health care
delivery (as shown in Figure 1) [2].
hit
Trial-and-error medicine
Figure 1: Personalized medicine facilitates the





targeted selection of a treatment with the highest likelihood
Why is personalized medicine thought to hold such potential? In almost every disease area, only
a subset of patients will benefit from a given drug therapy, while the remaining patients will fall
victim to the "trial-and-error" methodology of medicine that is still widely practiced in the United
States. For example, adverse drug reactions occur in 10-20% of all hospital admissions, of which
10-20% are considered severe or life threatening [3], and some people estimate that at least 40%
of patients taking a given therapy may not benefit from it [4]. These startling statistics are side
effects of the traditional drug development paradigm, in which therapeutic compounds are tested
through clinical trials in a small group of individuals who poorly represent the wider population
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of patients who will eventually take the drug. Steven Epstein's 2007 book, Inclusion: The Politics
of Difference in Medical Research, highlighted the ethical, political, and sociological consequences
of implementing this one-size-fits-all paradigm of medicine, in which observations from a single,
homogeneous group of clinical trials patients are generalized to entire populations of individuals
of different genders, ages, races, and socioeconomic backgrounds [5]. While Dr. Epstein focused
on the phenotypic and demographic characteristics of patients, the same principles can be applied
to genetic variation - a significant proportion of variance in drug response can be attributed to
the DNA-based variations between individuals [6], and drug trials will likely be limited in their
predictive value if they involve subjects whose genetic makeup does not closely mirror that of the
targeted patient population.
Therefore, the implementation of personalized medicine relies on the ability to determine a patient's
germ line or somatic genomic makeup, which in turn allows physicians to link the genomic signature
to a diagnosis, prognosis, or prediction of therapeutic efficacy. The invention of technologies for
querying a tissue sample at the molecular level has enabled the creation of clinical genetic tests in
several application areas, including oncology, infectious disease, and pharmacogenomics [7]. While
many "early adopter" physicians within large academic hospital centers make regular use of genetic
tests, diffusion of these innovations to other health care providers, the majority of whom practice
in community-based hospitals and private clinics, has not yet been observed. For example, in 2007,
after three years on the market, Genomic Health delivered 24,500 tests using its Oncotype DX
gene expression assay for breast cancer prognosis [82], but the incidence of node-negative, estrogen
receptor-positive breast cancer, which is the tumor type targeted by Oncotype DX that accounts
for about half of the breast cancer diagnoses in the U.S. [81], was nearly 90,000 in that same year
[8]. This indicates that the utilization of Oncotype DX has yet to diffuse through the population
of physicians who treat approximately 72% of the target patient population.
Even the small sample of genetic tests examined in this thesis highlight the puzzle surrounding the
development and adoption of these important medical advances: while the value proposition for
personalized medicine is clear, in fact, very few genetic tests have been rapidly and comprehensively
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adopted in the clinical setting. It is this puzzle of slow adoption that lies at the heart of this thesis.
Genetic tests are embedded in the broader health care system, which is fraught with complexities in
the form of regulatory policies, indirect payment systems, and asymmetries of information between
caregivers and patients. Any one of those elements may present barriers to the widespread adoption
of these innovations (or any medical product, for that matter). We acknowledge these dynamic
forces and their role in product diffusion, but we also seek to elucidate other forces that may not
have received their share of attention in past research.
By using innovation diffusion theory, we aim to characterize the diffusion of four genetic tests and
bring new perspectives to the theory in the context of the unique technical and institutional fea-
tures of personalized medicine. Innovation diffusion theory, which has its foundations in Everett
Rogers' 1962 book, Diffusion of Innovations [9], has been used for decades to study and explain
the adoption patterns of new products amongst populations of users. This model lends itself well
to the study of innovations in health care, and as we discuss later, many researchers have applied it
to medical products and practices, starting with the classic study of the antibiotic tetracycline by
James Coleman in 1966 [10]. However, few studies have focused on the diffusion of genetic tests in
the context of personalized medicine, despite the fact that these innovations exhibit unique char-
acteristics (like the need to interpret a multivariate genomic report) that may result in deviations
from traditional diffusion patterns that have been observed in drugs and medical procedures [11].
In addition, the role of certain third-party stakeholders in the clinical adoption of new medical
innovations has not yet been explored empirically. Specifically, evidence points to the potential
importance of medical professional societies, and disease foundations and patient advocacy groups
("patient groups") in the diffusion of genetic tests. At a recent Institutes of Medicine workshop,
a representative from Genzyme Genetics hypothesized that the addition of the EGFR genetic test
to the National Comprehensive Cancer Network's practice guidelines for non-small-cell lung cancer
would aid in the diffusion of those tests [11], and while our clinical expert interviewees supported
that presumption, it has not been tested analytically. Similarly, patient groups have exercised
their influence over many areas of medical innovation [12], including a case in which the Dutch
Breast Cancer Association successfully lobbied for reimbursement to cover the administration of
trastuzumab for breast cancer patients in the Netherlands [13]. A comment in the proceedings from
another Institutes of Medicine workshop implied that uptake of BRCA1/2 testing may be more
rapid "if there is an advocacy group that is pushing for BRCA-1 or -2 testing in your community"
[38]. The relationship between patient groups and genetic test adoption has not yet been empirically
explored, though the history of involvement from patient groups in the propagation of treatment
access and awareness indicates that they may be a significant force in this respect.
We focused on the area of breast cancer diagnosis and treatment, since it represented the largest
market for genetic tests in 2008 [62], and therefore has a sufficient number of examples of genetic
testing products that exhibit a variety of characteristics that are relevant to our study (see Figure
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Figure 2: 2008 market sizes for cancer genetic tests
This was also a compelling area of study because of anecdotal accounts of differences in adoption
patterns between genetic tests with similar indications. One example is the disparity between
Genomic Health's Oncotype DX and Agendia's MammaPrint, both of which have prognostic appli-
cations for recently diagnosed breast cancer patients, but the latter of which has not been able to
gain acceptance by key organizations relative to its competitor [14]. Oncotype DX also has pharma-
cogenomic uses with respect to the administration of adjuvant chemotherapy in conjunction with
tamoxifen and has been adopted for that purpose, while Roche's AmpliChip CYP450, which can
help guide the dosage of tamoxifen, has reportedly experienced slow growth and low adoption [93].
Why has Oncotype DX shown favorable clinical adoption, while MammaPrint and AmpliChip sales
have dwindled? Through this thesis, we intend to identify a set of criteria that can discriminate
between the former and the latter.
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Variables hypothesized to have positive correlation with clinical adoption





---- - -- - -- ----- -----Variables hypothesized to have negative correlation with clinical adoption
Figure 3: Variables of interest and their hypothesized correlations with genetic test adoption
We hypothesize that the diffusion of genetic tests is driven by a combination of factors that have
been studied previously ("traditional factors") and factors that have yet to be evaluated empirically
("novel factors") in the context of the diffusion of a medical innovation. Traditional factors include
the price of the test [15][16][17][30] and intellectual property [18][19][20]. Novel factors include
the regulatory path through which the test is brought to market, strength of clinical evidence,
and endorsements from medical professional societies and patient groups. In relation to Rogers'
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original model, price, patents, and clinical evidence are characteristics of the innovation, while
the regulatory bodies (e.g. the Centers for Medicare and Medicaid Services, or CMS, and the
Food & Drug Administration, or FDA), professional societies, and patient groups are third parties
that may affect the shape of the diffusion curves. Based on the anecdotal information mentioned
earlier, we postulated that the test price and FDA approval would be negatively correlated with
clinical adoption, while the strength of IP, clinical evidence, professional society endorsement, and
patient group endorsement would be positively correlated. Figure 3 shows these variables and
their supposed forces on the adoption of genetic tests.
The remainder of this thesis is organized as follows.
We first provide background information on the three conceptual foundations of our study:
1. Innovation diffusion theory, which is the framework we employ to reflect on the clinical
adoption of novel medical products.
2. Genetic tests, of which four are the subject of our evaluation.
3. Breast cancer, which we use as the clinical backdrop for our survey of technology factors
and institutional arrangements, and their association with the adoption of genetic tests by
physicians.
We then describe the methodology for genetic test selection and data collection, demonstrate how
we derived certain dependent and independent variables, and then outline the proposed framework
for analysis. The results of our study are presented in the form of Test Scorecards, accompanied
by written descriptions of our test-specific findings. Finally, we discuss the implications of our
findings for various stakeholders in the development, commercialization, and utilization of genetic
tests, present some potential limitations of our study, and propose secondary hypotheses that are
ripe for further evaluation based on our findings.
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Figure 4: The innovation adoption and diffusion curves proposed by Everett Rogers in 1962
Everett Rogers' landmark book, Diffusion of Innovations, has synthesized, through multiple edi-
tions, the results of over 500 diffusion studies that examine everything from the adoption of hybrid
seed corn to the practice of boiling water, including the foundational study by James Coleman
on the diffusion of tetracycline through four communities of physicians in Illinois [9][10]. In his
original formulation, Rogers focused on the personal characteristics and perceptions of users and
the external influences by colleagues, organizations, or societal forces as the driving forces behind
the adoption of novel innovations, which can be technologies, products, ideas, or practices. His
"innovation adoption curve" showed that the diffusion of an innovation, in terms of the amount
of time a user takes before deciding to adopt it, follows a normal distribution, and that one can
... .. .
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discriminate between five categories of users along that curve: the early innovators, early adopters,
early majority, late majority, and laggards (see Figure 4).
Key tenets of diffusion theory
From these studies, we can extract at least four key tenets: firstly, the factors that affect the
speed with which an innovation diffuses through a user community include the characteristics
of the innovation itself, the actions and interests of relevant third-party organizations, and the
characteristics of the potential adopters [21]. In the case of medical technologies, the characteristics
of the innovation may include the efficacy of a drug or the ease of implantation of a medical
device. Relevant third-party organizations may be regulatory bodies, payers, professional societies,
and product manufacturers. The definition of "end user" in the context of medical products is
subject to interpretation; some studies have considered physicians as the end users, since they
ultimately make the decision to prescribe treatments or procedures, in most cases. Other studies
have considered the patient to be the end user, especially in the context of products that may be
somewhat discretionary, like genetic tests for predicting susceptibility to common diseases [26].
Secondly, as shown in Figure 4, users can be split into 5 categories based on their relative levels
of "innovativeness." Rogers noted that individuals differ across these categories in their levels
of risk aversion, age (innovators and early adopters tend to be younger), social status, financial
wherewithal, and the size and nature of their social and professional networks [9].
Thirdly, the diffusion of innovations can be described through a 5-stage process. The first two
stages, which comprise the "dissemination process," involve building awareness in the potential
user population and persuading individuals to adopt the innovation. The subsequent three stages
comprise the "adoption process" - in the first step, the user decides to either accept or reject the
innovation based on a combination of personal judgment, trial-based outcomes, or peer opinion. If
she chooses to become an adopter, she then moves into the implementation stage, during which she
changes her behavior to accommodate the regular use of the innovation. The final confirmation
stage involves maintenance of the routine use of the innovation, which is facilitated by reinforcement
through a positive feedback loop.
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Finally, the speed at which a user moves through these five steps is dependent on three categories
of factors:
1. The user's perception of the innovation plays a major role in determining whether she passes
through the persuasion stage. The dimensions of perception include:
* The advantage of the innovation relative to existing substitutes,
* The compatibility of the innovation with existing processes and workflows,
* The level of complexity of the innovation,
* The ability to test the innovation before adopting it,
* The ability to observe the results of the innovation,
* The flexibility with which it can be integrated into one's life, and
* The potential social or material consequences of adoption.
2. The characteristics of the user herself are important determinants of whether or not, and how
quickly, she adopts the innovation. The aforementioned 5-category innovativeness scale can
be used to characterize the user, and the dimensions of perception in the previous paragraph
may have different weights across the user categories. For example, the ability to test the
innovation before adopting it may be less important to a laggard, who simply follows the
leads of others, than it is to an early adopter.
3. Contextual factors involving third party organizations can either facilitate or inhibit the
spread of the innovation. These could be organizational attributes, like hierarchies, company
policies, or cultural openness to new innovations, or they could be forms of communication,
like marketing messages from the company who has manufactured the innovation or approval
rulings from a regulatory body [9].
The case of tetracycline
The diffusion study on tetracycline was the subject of the 1966 text, Medical Innovation: A Dif-
fusion Study [22]. Several years before the publication of the book, Pfizer, the drug manufacturer,
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had set out to study the effectiveness of its journal-based advertising campaign for tetracycline by
collaborating with a team of sociologists at Columbia University (Coleman, Katz, and Mendel).
This marketing study ballooned into a groundbreaking investigation of the social drivers of in-
novation diffusion, resulting in the first major study to model diffusion as a social process that is
dependent on the level of interpersonal communication between users (in this case, physicians) [23].
The influence of third-party organizations and social networks was also examined; for example, the
research team evaluated the role of pharmaceutical sales representatives and the provisioning of free
samples in the adoption of drug prescribing practices, as well as the influence of journal publications
and information presented at conventions run by medical professional societies. It concluded that
active networking and word of mouth were the main drivers of adoption amongst physicians, as
demonstrated by the fact that the diffusion of tetracycline prescribing behaviors was faster among
doctors with rich professional networks than those who were more isolated from their peers.
Other studies of diffusion in medicine
Numerous research teams followed suit, also leveraging Rogers' theory to measure the diffusion of
various health care technologies and practices through the medical establishment. Given the focus
of our research, we conducted a search of the peer-reviewed literature to identify studies that dealt
with the diffusion of genetic tests or other personalized medicine-related technologies and practices,
examined what we labeled as our "traditional factors" in the introduction of this thesis, or provided
evidence to support the evaluation of our "novel factors". A representative set of studies is listed
in Table 1; those that qualify as true diffusion studies are labeled as such, while the remainder are




1: Representative literature on the diffusion of medical innovations
Subject Description
Impact of medical norms on Showed that genetic counseling will likely
adoption of genetic experience difficulty in being widely adopted
counseling because it requires a departure from
traditional interventional practices to a more
preventative form of medicine.
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[continued from previous page]
Authors Year Subject Description Diffusion Ref.
study?
Holtzman 1992 Diffusion of genetic tests for Predicted that genetic tests will become N [25]
disease prediction accessible to the public through primary care
physicians, and potentially promoted through
government-mandated testing programs or
direct-to-consumer channels; proposed
potential barriers of costs and fear of
discrimination by insurers.
Armstrong, 2003 Early adoption of BRCA Applied diffusion theory to determine that Y [26]
Weiner, testing the "innovativeness" of a patient and the
Weber, and perceived compatibility of the tests with
Asch personal beliefs and values correlated with
early adoption of BRCA1/2 genetic testing in
the University of Pennsylvania Breast and
Ovarian Cancer Risk Evaluation Program
(BCREP).
Cho, 2003 Survey of 122 clinical lab 53% of respondents were discouraged from N [20]
Illangasekare, directors to determine the developing at least one genetic test because of
Weaver, impact of gene patents on patent-related restrictions; the overall
Leonard, and the ability to deliver genetic sentiment about the effect of patents on the
Merz tests cost, access, and volume of development of
genetic tests was negative.
Mouchawar, 2003 Adoption and Guidelines across HMOs may differ slightly; Y [27]
Valentine, implementation of only half of the physicians surveyed were
Somkin, et al. hereditary breast and aware of guidelines set forth by their HMO.
ovarian cancer genetic
counseling
Suther and 2003 Barriers to the adoption of Concluded that genetics educational Y [28]
Goodson genetic counseling, testing, programs were needed to facilitate the
and interpretation services implementation of genetic services across a
wider set of physicians
Prosser and 2004 Qualitative study to While most physicians considered price to be Y [17]
Walley determine the role of price an important factor in prescribing decisions,
in prescribing behaviors no direct correlation was found between price
and prescription levels
Shah 2004 Criteria influencing the Described a four-part conceptual framework N [29]
clinical uptake of for evaluating pharmacogenomic tests with
pharmacogenomic tests respect to clinical uptake; the framework
consisted of the following: 1) medical need, 2)
clinical validity and utility of the test, 3) ease
of use of the test, and 4) choice of treatments
based on the results of the test.
Kieran, 2007 Role of price in clinical Showed that the relatively high price of the Y [30]
Loescher, and acceptance of BRCA testing BRCA genetic test played a significant role in
Kim discouraging patients from opting for the test.
Chauhan and 2008 Review of 29 studies on Found evidence that clinical trial Y [15]
Mason determinants of adoption of investigators and pharmaceutical sales reps
new therapies by specialists play a key role in adoption, while the price of
therapy and patient influence are weak factors
Shields, Burke, 2008 National survey of U.S. Of the 1,120 physicians who responded to the Y [31]
and Levy physicians on the use of survey, 60% had ordered a genetic test, and
genetic tests 74% had referred a patient to a genetic
counselor or specialist. Showed that
physicians serving ethnic minorities were less
likely to have applied genetic testing or
referral services.
[continued on next page]
[continued from previous page]
Authors Year Subject Description Diffusion Ref.
study?
Smits and 2008 Role of "users" (patient Used three case studies to argue for a N [13]
Boon advocacy groups, medical systemic approach (rather than a linear
professional societies, and approach) to medical innovation, in which
insurance companies) in third party players are given a voice in the
pharmaceutical innovation innovation process; not a diffusion study, but
provided evidence of patient advocacy groups
as a relevant factor in innovation.
Issa, Tufail, 2009 Focus groups to assess While patients generally supported the use of N [12]
Hutchinson, patient readiness for pharmacogenomic tests, they were concerned
Tenorio, and pharmacogenomic testing about privacy of the test results; patients
Baliga expressed more willingness to pay for tests
associated with high risk diseases like cancer
than those associated with chronic disease.
Pierce, 2009 Four case studies to Did not find evidence that the N [19]
Carlson, determine if fragmented commercialization of genetic tests were in any
Kuszler, patent ownership has way inhibited by fragmentation of intellectual
Stanford, and inhibited the property.
Austin commercialization of clinical
genetic tests
As seen in this collection of research, past diffusion studies have mainly focused on physician
characteristics (e.g. Shields, et al. showed that a physician's age was inversely correlated with
adoption of genetic testing practices, and that physicians who had ordered genetic tests were nearly
twice as likely to have received formal training in genetics [31]), product attributes (e.g. Kieran,
et al. found that the high price of BRCA testing seemed to discourage patients from seeking the
genetic testing service [30]), and the level of "innovativeness" of patients (e.g. Armstrong, et al.
studied the characteristics of early adopter patients who chose to undergo BRCA testing [30]).
While Coleman's original study evaluated the role of conferences held by medical professional
societies, we found no studies that explicitly examined the correlation between inclusion in practice
guidelines and clinical adoption, though it has been postulated that this factor can play a key role
in the diffusion of genetic tests [11].
Also, there has been little empirical research of which we are aware that evaluates genetic tests
on the basis of the primary characteristics that are highly relevant in molecular diagnostics, like
the strength of clinical evidence and status of regulatory approval, though we know anecdotally
that these two factors differ across the Oncotype DX and MammaPrint tests and may explain their
discordant rates of adoption. Finally, no systematic analyses have evaluated the role of disease
I---~--------- ~--""~  C~L ~ 
- - -- - - 1
foundations and patient advocacy groups ("patient groups"), though researchers have provided
evidence that supports the importance of patient groups in the diffusion of medical innovations,
generally speaking. It is yet to be seen whether that association carries over from drugs to genetic
tests.
Empirical subject - genetic tests
Our study focuses on four genetic tests, which are tools that can be utilized in a laboratory, at the
point-of-care, or in a home-based setting to perform an analysis of DNA or DNA-based products,
including chromosomes, genes, genetic polymorphisms, mutations, and mRNA transcripts. Some
definitions of genetic tests also include testing of the proteins that are created through transcription
and translation of DNA [34]. Genetic tests can identify biomarkers, including rare, pathogenic
mutations, common polymorphisms, and genetic expression signatures, that can be used to diagnose
disease, assess disease susceptibility, determine disease prognosis, or predict treatment response in
a patient. While most genetic tests focus on germ line mutations, or those mutations that are
inherited from one's parents, some tests focus on somatic mutations, which arise de novo in adult
tissue, as is often seen in cancer cells. Several examples of applications of genetic tests are listed
in Table 2.
Operational aspects of genetic testing
The genetic testing process begins with a consultation between the patient and a genetic counselor
or other specialist who evaluates the patient's family history, explains any relevant options for
testing, sets realistic expectations for the results and their actionability, and discusses the potential
consequences of obtaining a genetic test. The actual testing will only be conducted after the patient
indicates that she has given informed consent. Once that is complete, a sample of blood, saliva, or
tissue is taken from the patient, stored, and delivered to the laboratory, which could be a large lab
that offers hundreds of different routine tests (e.g. LabCorp and Quest Diagnostics), or a small,
proprietary lab that only runs a single test or a panel of tests for specific indications (e.g. Genomic
Health). Once the sample is processed to extract and purify the DNA or RNA molecules, the
resulting genomic material is then evaluated using the relevant technology - for example, DNA
Table 2: Illustrative examples of genetic testing applications
Type Description Examples
Carrier Used by parents when planning to Cystic fibrosis, cleft lip
identification conceive to check for recessive
disorders that may be passed onto
offspring
Prenatal diagnosis Used to identify genetic disorders in Trisomy 21
utero
Newborn screening Preventative measure to detect rare Phenylketonuria
genetic diseases, for which a cure
typically exists
Predictive Determine relative risk for developing BRACAnalysis test for analyzing
a condition with genetic basis susceptibility to breast cancer
Monitoring and Evaluate or predict progression of a OncotypeDX for breast cancer
Prognosis disease in an already diagnosed prognosis
individual
Pharmacogenomics Tests to predict response or dosage of HER2/NEU biomarker to predict
therapeutics response to transtuzumab; CYP2D6 to
predict response to tamoxifen
Source: http://ghr.nlm. nih.gov/handbook/testing/uses
may be hybridized to a microarray chip in order to determine which alleles of a gene the patient
harbors, as described in the next section.
The operational aspects of the tests we evaluate in this thesis vary quite a bit. For one, the
BRACAnalysis and Oncotype DX tests are conducted in company-managed laboratories, to which
all samples must be sent. This may limit the scalability of the testing service, in that large capital
investments may be required to build new laboratory space every time the company needs to
expand its capacity. Conversely, MammaPrint and AmpliChip CYP450 have been approved by
the FDA as manufacturer developed kits (MDTs), meaning that the kits can be distributed to any
lab and performed according to an instruction manual. While this removes some of the burden
of scalability from the manufacturer, the purchasing laboratories may still need to make large
investments in capital-intensive equipment, as we later discuss in the context of the AmpliChip kit
and its associated machinery. The operational aspects of genetic tests are not evaluated analytically
in this thesis, but they may affect genetic test diffusion curves for some of the reasons we mentioned
above.
Genetic testing technologies
Numerous technology platforms and methodologies exist for performing genetic tests. According to
GeneTests.org [35], the three major categories of genetic test technology are: DNA-based (molec-
ular), cytogenic, and biochemical. While dozens of different technology platforms fall into these
three categories, we focus on the recently developed "high-throughput" molecular diagnostic tech-
nologies of RT-PCR, microarrays for gene expression and genotyping, and whole gene sequencing,
which are described below.
Reverse transcription polymerase chain reaction, or RT-PCR, is the process through which small
amounts of mature mRNA transcripts are reverse transcribed into their complementary DNA coun-
terparts, and then amplified many-fold for analysis. This technique allows for the determination of
both the genetic sequence in an individual's genome, as well as the level of expression of a given
gene in a tissue of choice. RT-PCR is a derivative of polymerase chain reaction (PCR), which deals
directly with DNA rather than mRNA. One of the benefits of RT-PCR is that it assesses only the
coding regions, or exons, of the genome, since the introns, or non-coding regions of the genome, are
spliced out of the transcripts before they become mature mRNA [36].
Microarray analysis is undertaken using miniature chip-based products that enable either the deter-
mination of gene expression profiles using the mRNA extracted from tissue samples, or the primary
sequence of gene regions of interest for the purpose of identifying variants. A microarray chip can
contain up to hundreds of thousands of oligonucleotides, or short, single-stranded DNA sequences,
to which the complementary mRNAs or DNAs from the tissue sample hybridize. When measur-
ing gene expression, the amount of mRNA that hybridizes to a given oligonucleotide is observed
quantitatively to determine the level of expression of that gene or gene region in the sample. For
the identification of genetic variants, a microarray chip will contain 4 versions of the same gene
region that differs by only one nucleotide, and the sample DNA will hybridize to one or two of
those oligonucleotides to denote homozygosity or heterozygosity, respectively [37].
Whole gene sequencing produces a high-resolution map of the nucleotides in a particular part of
an individual's genome. Direct sequencing, which is the method employed by Myriad Genetics,
determines the nucleotide sequence of a specific region of the genome (e.g. a gene, or a coding
region within a gene) that has been amplified through PCR.
The technology platform underlying a genetic test may affect the price at which the test can be
made available, the operational ease with which the test can be performed, and the accuracy of
the results. While we do not explicitly evaluate technology platforms as independent variables in
this thesis, all of these secondary factors may contribute either directly or indirectly to the clinical
adoption, or lack thereof, of a genetic test.
Genetic test results
The results of a genetic test can guide a physician in her use of preventative care, and help determine
at what age the preventative care should begin. For example, should an individual receive more
intensive screening through breast MRIs in her 30's, rather than the standard annual mammog-
raphy regimen beginning at age 40? Should she receive chemopreventative agents to help prevent
cancerous tumors from ever forming? Some of the genetic tests we evaluate in this study are also
used in the treatment setting, after an individual has already been diagnosed with a disease. Those
genetic tests may be used to guide treatment; for example, should the patient receive adjuvant
chemotherapy to prevent distant recurrence, or can she avoid the risk of the off-target toxicity that
is so common with that treatment strategy [38]? Genetic counselors play a key role in preparing
the patient for the choices that she will have to make with her physician based on the results of
the genetic test.
Like all clinical measures of physiology and medical history, the results of a genetic test need to be
evaluated in the context of an individual's history, co-morbidities, and physiological risk factors. To
complicate matters, the results of a genetic test are not always definitive or complete. For example,
Myriad's BRACAnalysis Multisite Analysis looks for three specific mutations in the BRCA1 and
BRCA2 genes that are prevalent in the Ashkenazi Jewish population, but a negative test result
does not rule out the possibility that the individual harbors a pathogenic mutation that was not
covered by the test. In addition, Myriad's BRACAnalysis Comprehensive Analysis, which analyzes
the whole gene sequence, may identify a mutation of unknown significance (one that has either not
_ ____II_ _~__C~ I__ _ _ ------s~-- 1_1__11___ 1 I_ ---P-
been observed in other individuals, or has not definitively been labeled as a benign or pathogenic
mutation), in which case the burden falls on the physician to make a call that mitigates the health
risk for the patient, while not causing undue distress.
Because of the operational, technical, and interpretive complexity of genetic tests, the physicians
who prescribe the tests may face unique challenges that they do not encounter with drugs or devices.
For the more complex multivariate tests that involve computational algorithms, the interpretation
may be an overwhelming task that discourages adoption by physicians. Also, while a drug is a
tangible good that the physician can directly administer to the patient, a genetic test is typically a
"black box" that operates outside of the point-of-care setting. Thus, genetics tests oftentimes lack
the "trialability" that is a key factor in diffusion, according to Rogers' original theory.
These facts point to the need for diffusion studies that account for the differences between genetic
tests and other medical products and that also elucidate novel factors that may better explain
diffusion patterns for genetic tests.
Empirical setting - breast cancer
Breast cancer provides a rich setting for the study of the diffusion of genetic tests. It is one of
the leading causes of death and the single most common form of cancer in women in the United
States. According to the American Cancer Society, about 240,000 new cases of breast cancer were
diagnosed in 2008, and a woman living in the U.S. has about a 12.7% lifetime risk of developing
the disease [39]. The high prevalence and incidence of the disease, paired with poor survival rates
in patients who are diagnosed with late stage cancer, makes it important from both a population
and a health economics perspective.
A 2007 Cancer Trends Progress Report estimated that annual expenditures on breast cancer-related
medical care reached $8.1 billion [40], and a significant proportion of that spending likely went to
systemic treatments, like chemotherapy, that resulted in off-target toxicity, or monoclonal antibod-
ies, like trastuzumab, that were non-efficacious. Less than 20% of breast cancers are estimated
to over-express the HER2 gene, so if trastuzmab (the targeted therapy for HER2 over-expressing
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tumors) were administered to all breast cancer patients, at least 80% would likely not benefit from
the therapy, and the annual drug cost of about $40,000 per patient would go to waste. In addi-
tion, the results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 study
showed that, of the 55% stage 1 or 2, node-negative, ER+ breast cancer patients who received
adjuvant chemotherapy in addition to tamoxifen, about 70% were likely put at unnecessary risk
of chemotherapy-related toxicity because their risk of recurrence was so low that the benefits of
chemotherapy were minimal [41]. The introduction of HER2 testing and the Oncotype DX assay
changed the dynamics of these two scenarios by making it possible for oncologists to tailor their
therapeutic strategies based on the molecular nature of the tumors in each of their patients.
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Figure 5: The landscape of genetic research, associations, and tests in breast cancer
Because of these opportunities to improve the prevention, screening, and treatment of breast cancer,
scientific research has been prolific, resulting in a burgeoning body of literature and data, as seen
Figure 5. The overwhelming number of results for a search on the phrase "breast cancer" on theFigure 5. The overwhelming number of results for a search on the phrase "breast cancer" on the
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National Centers for Biotechnology Information's (NCBI) Entrez website demonstrates the high
level of scientific productivity with respect to the identification of genes across multiple species of
organisms that are implicated in the process of breast cancer development, metastasis, prognosis,
and therapeutic effect. From the 200,000+ results, we find that over 1,150 genes have been shown to
have correlation (either causative or associative) to breast cancer in humans. Specifically, scientists
have located specific mutations in the BRCA1 and BRCA2 genes that are highly penetrant for
hereditary, early-onset breast cancer, while germ line mutations in other genes may result in an
increased risk for breast cancer as part of a spectrum of cancer-related syndromes, like Cowden's
syndrome and Li Fraumeni's syndrome.








2005 2006 2007 2008 2009E 2010E
Figure 6: Total NIH spending on breast cancer, 2005-2010E (in $millions)
Despite the abundance of research and the formidable amount of NIH funding for this disease
area over the past few years (greater than $700 million each year for the past 5 years, ranking
41st out of 215 disease areas that received NIH funding [42]; see Figure 6), only 8 of the human
breast cancer-related genes have been translated into clinically available single gene tests, while
only 2 multivariate genetic tests, referred to by the FDA as "in vitro diagnostic multivariate index
assays", or IVDMIAs, have been developed for the determination of disease prognosis in a subset
of breast cancer patients. Of the 8 single gene tests, 3 leverage older cytogenetic technologies like
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and the remainder use
modern molecular diagnostic technologies like microarrays and whole gene sequencing. One of the
multivariate assays uses RT-PCR, while the other is a microarray-based test. These gene tests are
discussed in the next section.
The genetic basis of breast cancer
Table 3: Genes associated with breast cancer with commercially available genetic tests
Gene Gene name Chromosome Category Percentage of Is testing
symbol(s) locus breast cancers standard
with mutations of care?
BRCA1 breast cancer 1, early 17q21 Susceptibility 5-10% Y, for
onset high-risk
BRCA2 breast cancer 2, early 13q12.3 Susceptibility 5-10% Y, for
onset high-risk
PTEN phosphatase and tensin 10q23.3 Susceptibility 5% with Y, for
homolog (associated with mutations; 25% high-risk
Cowden's Syndrome) with decreased [44]
expression [43]
P53/ TP53 tumor protein p53 17p13.1 Susceptibility, 20% in all breast Y, for
(associated with Li Prognosis cancer patients; high-risk
Fraumeni's Syndrome) 100% in those with
BRCA mutations
[45]
HER2/ v-erb-b2 erythroblastic 17q21.1 PGx 10-20% [46] Y




ER/ESR1 estrogen receptor 1 6q25.1 PGx 70-75% [47] Y
PR/PgR progesterone receptor 11q22-q23 PGx 60% Y
CYP2D6 cytochrome P450, family 22q13.1 PGx 1-5% in Asians, N
2, subfamily D, 5-10% in
polypeptide 6 Caucasians [48],
3% in Africans [49]
The genes associated with breast cancer can be classified into those that increase susceptibility for
early-onset forms of disease, those that assess patient prognosis, and those that predict response
to treatment (pharmacogenomics). Table 3 contains a list of genes that have been translated into
commercially available gene tests in each of these areas. As can be seen in the right-most column of
the table, only a subset of these genes have been incorporated into the standard of care for breast
cancer care, and many of them were only incorporated into official professional guidelines in recent
years (2008, 2009).
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Genetic tests for susceptibility
Individuals who are at high risk for breast cancer based on personal or family medical history may
choose to undergo susceptibility testing. Figure 7 contains a representation of the clinical decision
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Figure 7: Clinical decision tree for hereditary breast cancer genetic testing (derived from expert interviews
and 2009 NCCN guidelines)
Before an individual has his or her genes tested, the primary care physician or specialist will apply
one of several available algorithms to determine the probability that the individual is a carrier of
a mutation in the gene of interest. For example, there are at least seven models for predicting the
likelihood that an individual is a BRCA1 or BRCA2 mutation carrier [51].
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Genetic tests for invasive breast cancer
The two high-level categories of breast cancer are non-invasive and invasive; the former occurs within
the breast and does not display metastasis, or spreading to other areas of the body, while the latter
is characterized by either a metastatic cancer or a lesion in which the tumor cells have compromised
the border of the lesion. Patients with non-invasive breast cancers typically do not make use of
genetic tests for major treatment determinations, so we focus on invasive breast cancers for this
study of genetic tests. Figure 8 represents the clinical decision tree for invasive breast cancer
patients and shows the points at which genetic tests related to prognosis and pharmacogenomics
are indicated for use.
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Figure 8: Clinical decision tree for treatment selection in patients with invasive breast cancer (derived from
expert interviews and 2009 NCCN guidelines)
The initial set of clinical decisions for invasive breast cancer patients revolves around the results of
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the hormone receptor and HER2 expression assays, which classify the patient's tumor into one of
five categories (Luminal A, Luminal B, "triple negative" or basal-like, hormone receptor-positive
HER2-positive, and hormone receptor-negative HER2-positive). The CYP2D6 genotyping test for
predicting the individual's drug metabolism profile based on germline polymorphisms is currently
not considered to be part of the standard of care, while the ER/PR, HER2/NEU, and Oncotype
DX tests are now recommended in the standard guidelines by major professional societies, including
NCCN and ASCO, as discussed below.
Methodology
We collected and derived both qualitative and quantitative data on four breast cancer genetic tests
and implemented a case study-based approach to evaluate the hypothesis that the diffusion of
novel genetic tests for personalized medicine applications can be described using variables beyond
those that have been explored in previous studies. The variables that we studied were: 3 primary
characteristics of the tests themselves, data from clinical studies for validation, utility, and cost-
effectiveness, inclusion in the professional guidelines of medical professional societies, and implicit
or explicit endorsement by patient groups. Data were generated from a combination of expert
interviews, primary literature searches, gray literature searches, and general internet searches.
Interviews with 3 industry experts and 2 clinical experts were conducted in person during the
months of February, March and April of 2009. The 3 industry experts were C-level or VP-level
executives at their respective companies, and had been involved in the strategic decision making
processes when their respective companies were developing genetic testing products. Questions for
these individuals focused on the strategic aspects of commercializing a molecular diagnostic test,
including determination of the optimal regulatory framework, reimbursement strategy, and clinical
validation. The 2 clinical experts were both practicing physicians at a large, Boston-based academic
medical center; one had expertise in breast cancer as an oncologist, while the other was an expert
on the diagnosis of breast cancer in the radiology clinic. Questions for these individuals dealt with
the standard of care for breast cancer, utilization of genetic tests, the role of professional societies,
and clinical algorithms for breast cancer prevention and treatment.
~~~~ -------
The majority of the data supporting this research was extracted from peer-reviewed journals, which
were accessed through searches in the PubMed and ISI Web of Science interfaces. All relevant
sources are listed in the references section at the end of this report. Some unpublished whitepapers,
presentation materials, and conference proceedings were also referenced and were obtained through
personal contacts, referrals, or internet web searches. Google's web search, books search, patent
search, and Scholar properties were used as the primary sources for internet-based information and
data.
Selection of tests
We selected our set of tests based on the following inclusion criteria:
* Tests developed by a commercial organization. This filtered out tests that were de-
veloped as home-brew assays by hospital and academic labs. This filter was based on recom-
mendations from experts in the field, some of whom believe that academic and hospital labs
are often not fully CLIA-compliant.
* Tests developed using a proprietary technology platform, versus through a com-
modity technology. This ruled out home-brew tests offered by the likes of LabCorp and
Quest Diagnostics and limited our study to "value-based" genetic tests.
* Tests that leverage modern molecular diagnostic technologies. This limited the study
to those tests that were introduced during the most recent wave of diagnostics, ruling out
the hormone receptor tests that use cytogenic methods, like IHC and FISH, and leaving the
tests that use molecular technologies, like microarrays, RT-PCR, or whole gene sequencing
[53]. The intention here was to control for any biases related to technology generation effects
(i.e. to ensure that these tests were on the same part of the "Hype Cycle" as described by
Gartner Research [54]).
* For susceptibility testing, tests for genes known to be associated with Mendelian
forms of disease. This ruled out the "common SNP" test products that evaluate the genetic
polymorphisms that may predispose to common, or multigenic, forms of breast cancer. These
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loci have only been studied through genome-wide association studies, so they are generally
not considered to be clinically valid at this time. An example of a test of this nature is the
deCode Genetics BreastCancerTM test.
The list of the four tests that we analyzed for this study is displayed in Table 4.
Table 4: Breast cancer-related genetic tests selected for this study
Test name Company Category Year launched Technology
BRACAnalysis Myriad Susceptibility 1996 Direct sequencing
MammaPrint Agendia Prognosis 2007 Microarray
OncotypeDX Genomic Health Prognosis, 2004 RT-PCR
Pharmacogenomics
AmpliChip Roche Diagnostics Pharmacogenomics 2005 SNP microarray
CYP450
Measurement of clinical adoption
We measured the dependent variable of "clinical adoption" through two proxy variables: 1) the
number of assays performed per year, and 2) the existence of standard reimbursement through
CMS. The number of assays performed per year was taken directly from the literature or news
sources when available, or derived from other values and projections in reliable research reports.
Insurance coverage status was determined by information on company websites, press releases, and
CMS publications.
The independent variables were divided into three categories: 1) characteristics of the genetic
tests, 2) clinical validity, utility, and cost-effectiveness of those tests, and 3) endorsements of pa-
tient groups and medical professional societies. The characteristics of the genetic tests were deter-
mined through literature searches, expert interviews, and news articles. Reviews by the Agency for
Healthcare Research and Quality (AHRQ) and Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) Working Group were the primary sources of information on clinical validity,
utility and quality. Endorsements by the professional societies and patient groups were determined
through searches on the organizations' websites and through published guidelines. These variables
are described in more detail below.
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Dependent variables
Number of assays performed in 2007
We used 2007 as the baseline year for estimating the number of tests performed because that was
the most recent year for which reliable data could be found or calculated for all four tests. The
number of assays performed for MammaPrint was determined based on data that was presented
at the 2009 CHI Molecular Tri-Conference in San Francisco, CA. The value for Oncotype DX was
taken from Genomic Health's annual report. The values for the AmpliChip and BRACAnalysis
tests were calculated based on data in company reports, press releases, and market research reports.
Calculations are included in the appendix.
Reimbursement by CMS
Typically, The Center for Medicare and Medicaid Services (CMS) sets the standards for reimburse-
ment in the U.S., and private insurers will follow suit [55]. Since, by law, any medical service that is
reimbursed by CMS must be "reasonable and necessary [55]," we consider reimbursement by CMS
to be a sign that the use of a genetic test has been clinically accepted, thus making it a strong
proxy for clinical adoption in our study.
Independent variables
We treated the following factors as independent variables in this study: price, regulatory status,
intellectual property status, number of clinical validity studies, number of clinical utility studies,
number of health economics studies, number of endorsements by top medical professional societies,
and number of explicit and implicit mentions by the top breast cancer foundations. The methods
we used to measure each of these variables are discussed below.
Pricing
The price of each test was determined through information in press releases and company materials,
which were located through general internet searches. In the United States, pricing of genetic tests
is largely driven by the ability to gain reimbursement, namely through the Center for Medicaid
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and Medicare Services (CMS), but also through the numerous private insurers [56]. The American
Medical Association's coding system, called the Current Procedural Terminology (CPT) system,
is used by insurance companies to place a monetary value on a given medical procedure, which
in turn determines the level of reimbursement that the lab or hospital can receive for the proce-
dure. Medicare and Medicaid, administered by the U.S. federal government, refer to their more
comprehensive coding system as the "Health care Common Procedure Coding System" (HCPCS),
where Level I codes correspond directly to CPT codes, and Level II codes are designed for use by
non-physician health care providers [57].
Diffusion depends on the perception of an innovation of a potential user, and price is certainly a
factor that influences users' perceptions of a given product; if the price is prohibitive or if reim-
bursement does not cover the its use, the user is likely to be deterred from adopting. This issue
is particularly relevant to genetic tests, which are not universally covered through private payers
and can be quite expensive.The challenge for diagnostics companies has been to obtain value-based
reimbursement for their products, rather than payment that accounts only for the underlying op-
erational procedures of the test. A handful of value-based tests like Myriad's BRACAnalysis and
Genomic Health's Oncotype DX have been able to obtain what many consider to be "premium" re-
imbursement rates, which reflect the relatively high costs of basic research and clinical development
that the company must undertake in order to demonstrate the validity and utility of its test.
Strength of intellectual property
Patents enable an organization to exercise a temporary monopoly over a specific market based on
a unique technology or methodology, thus providing strong incentives for the commercialization
of proprietary products that require large investments of money and time. While the controversy
surrounding gene patenting and the patents that cover the testing of particular genetic character-
istics is beyond the scope of this thesis, it has provided rich detail regarding the patent coverage
of the human genome [58]. Perhaps the most well known patent portfolio in the genetic testing
space is that of Myriad Genetics, which, in 1997, obtained its first set of intellectual property rights
to specific mutations and testing methodologies for sequenced-based analysis of the BRCA1 and
BRCA2 genes.
A recent report showed that the effects of intellectual property on the pricing and development
time of genetic tests were negligible [59]. However, others argue that the costs associated with
legal due diligence, cross-licensing, and patent filing may deter other companies and organizations
from conducting research or investing in novel product development that leverages the knowledge
of a set of genes [60]. While gene patents have received their share of negative media coverage
for their perceived side effects of stifled innovation and competition, most technologically advanced
companies that make substantial investments in research and development for gene-related products
implement an intellectual property-based strategy for carving out a defensible operating space in
the market [62].
The strength of intellectual property around a product may alter users' perceptions, especially
when comparing two similar products and weighing the value of an investment in a product that
lacks patent protection and may therefore become obsolete or commoditized. Therefore, intel-
lectual property may be an important factor to consider when analyzing the diffusion of genetic
tests, though the debate over the general validity of gene patents still rages on. In our study, the
strength of a test's intellectual property was assessed as a qualitative measure based on the rating
system described in Table 5. This rating system depends on the number of patents protecting the
underlying technology and the geographical reach of those patents.
Table 5: Rating scale for strength of intellectual property
Rating Number of patents U.S. protection Ex-U.S. protection
Strong greater than 10 Yes Yes
Medium greater than 10 Either U.S. or ex-U.S.
Weak 10 or less Either U.S. or ex-U.S.
Regulatory approval or certification
Ongoing uncertainty exists in the genetic testing market regarding the optimal regulatory frame-
work within which a genetic test should be brought to market. Currently, a company seeking to
commercialize a genetic test can take one of two avenues:
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* Seek FDA approval for its test, which it could then market and distribute as a standardized
"manufacturer-developed test" (MDT), or
* Develop a "home-brew" test (or "laboratory-developed test" - LDT) under the terms of the
Clean Laboratory Improvement Act (CLIA), which governs the operational validity through
which the test is performed in a given lab [61].
The FDA approval process focuses on proving the prospective validity of a given assay, with respect
to two attributes: reliability of the technology and data and reproducibility across multiple testing
environments and operators. Examples of FDA-approved kits are Agendia's MammaPrint assay
for prognosis in breast cancer patients and Roche's AmpliChip CYP450 microarray, which aids
in dosing decisions for numerous drugs, including tamoxifen, which is used for estrogen receptor-
positive breast cancer tumors. FDA approval itself comes in two flavors: PMA and 510(k).
* Pre-market approval, or PMA, is the more arduous process, because it requires that the
company generate a de novo clinical data package for a novel indication that is not currently
addressed by existing products. A PMA allows the company to obtain new reimbursement
codes, so companies may see this as a way of obtaining value-based reimbursement that is
specific to their assay.
* For a 510(k), a company can leverage existing reimbursement codes by showing substantial
equivalence to a prior product. While the reimbursement rate for the product may be limited
to that which was established for the equivalent product, the time to market for commercial-
ization can be considerably shorter through this path than through the PMA path. Both the
AmpliChip CYP450 and MammaPrint tests received approval under this classification.
CLIA certification is the fastest and cheapest route of commercializing a test, since it does not
require clinical utility studies, though uncertainty around the FDA's presumed upcoming move to
regulate genetic tests makes this a potentially risky strategy. Tests developed through CLIA are not
required to undergo clinical validation studies prior to being marketed, though stringent regulations
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apply to the laboratory environment, materials, and methodologies through which the tests are
conducted. Some companies with commercial LDTs choose to conduct clinical validation and utility
studies despite the lack of requirement to do so because this data can influence reimbursement and
physician adoption, as we discuss in the next section; this was the case for Genomic Health when
they commercialized their Oncotype DX test.
Genetic testing companies face a key strategic decision when it comes to determining which regu-
latory path they will take for commercializing their products. FDA approval is perceived as being
a longer, more expensive, and more laborious pathway, given the administrative overhead of man-
aging the relationship with the government agency, the higher costs of doing larger clinical studies,
and the uncertainty of the length of time and outcome of the FDA review process. Therefore, most
genetic tests have been brought to market as LDTs, which is typically the cheaper and faster path,
and, as demonstrated by Genomic Health, a path that can be quite profitable if executed well [62].
Companies may also choose to commercialize their test quickly under the CLIA path, and then
pursue the FDA approval route once they have revenues to support the dual-pronged strategy, as
was the case with Pathworks Diagnostics and their Tissue of Origin Test.
Our clinical expert interviewees both stated that they generally look at FDA approval as a sign of
product validation that removes some (but not all) of the skepticism they have for any new medical
product that is introduced into their clinic. However, one of the interviewees admitted that her
regular use of Oncotype DX, which is not FDA approved, seems to invalidate her reasoning, so
other factors must exist that compensate for the lack of FDA approval when users decide to adopt
these tests. Our analysis includes an evaluation of regulatory approval as an independent variable
to confirm that FDA approval is negatively correlated with clinical adoption, but also to investigate
the relationship between this and other factors in the context of diffusion.
Each test was labeled as being brought to market under CLIA certification, FDA 510K approval,
or FDA pre-market approval (PMA) based on information from company websites and the FDA
database of CLIA- and 510(k)- approved products.
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Strength of clinical evidence
The strength of the clinical evidence that supports the use of a given test can be assessed through
three sub-factors: clinical validity, clinical utility, and health economics. Clinical validity measures
the statistical and analytical performance of a given test, or simply put, the ability of the test to
predict the phenotype that it claims to be able to predict. For molecular genetic tests, clinical
validity can be measured through prospective studies using archived tissue samples to see how well
the test can classify the samples into their known diagnostic or prognostic categories. Clinical
utility deals with the effectiveness of the test in leading to improved clinical decision-making and
provides input into risk-benefit calculations (e.g. does the test discriminate between patients who
will benefit from a specific therapy and those who will not without putting them at undue risk?).
Prospective, randomized controlled trials (RCTs) are the gold standard for determining clinical
utility. Health economics focuses on the cost-effectiveness of medical interventions. These studies
typically place a value on the intervention on the basis of quality-adjusted life years, or QALYs,
which assesses the cost of the test with respect to added lifespan and improved quality of life for
the patient.
Figure 9 below shows a rendering of the ACCE wheel, which was a model developed by the federal
Centers for Disease Control (CDC) for evaluating genetic tests that incorporates these principles
[63]. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working
Group applies this model to the evidence-based review of genetic tests, and we used data from
some of their reports to fill in the areas of the Test Scorecards dealing with clinical evidence.
Many stakeholders in the health care system use clinical evidence during the evaluation stages of the
adoption cycle to drive their decision to adopt a new medical technology; payers use the information
to determine coverage policies, while physicians may survey the clinical evidence of a genetic test
to ensure that they can confidently stand by the information they deliver to their patients via
the tests. Therefore, the strength of clinical evidence likely plays a role in the diffusion of genetic
tests, and may also have correlation with other variables we evaluate (for example, the strength
of clinical evidence may directly influence reimbursement status, which is one of our dependent
Figure 9: A CCE wheel: a framework for evaluating the clinical validity and clinical utility of genetic tests
variables, which in turn may influence pricing, another independent variable. We address this
potential confounding bias in the Discussion section).
We counted the number of clinical validity, clinical utility, and health economics studies associated
with each test, and also added qualitative assessments of the strength of those tests when necessary.
Inclusion in medical professional societies' practice guidelines
Most practicing health care providers are members of at least one or more medical professional
societies, which provide a platform for aggregating physicians and other health care workers and
facilitating the dissemination of valuable information on the evidence-based practice of medicine
through conferences, journals, and professional guidelines (which are particularly important to our
study). For medical professionals who focus on breast cancer genetic testing, the most notable pro-
fessional societies are the National Comprehensive Cancer Network (NCCN) and American Society
for Clinical Oncology (ASCO), as determined through expert interviews. These two organizations
publish annual (NCCN) or periodic (ASCO) guidelines on the evidence-based use of screening tests,
treatments, and prognostic tests for all cancer types, including breast cancer. The expert inter-
viewees who practice clinical medicine unanimously stated that they look to these guidelines as a
source of the most up-to-date information on accepted medical practices for treating breast cancer
patients, including use of genetic tests, which have recently made their way into the guidelines of
both organizations.
We expanded on the Coleman, et al. study by examining endorsements from medical professional
societies and their correlation with clinical adoption of genetic tests. Based on the principles
of diffusion theory, the role of these third parties and their inherent social networks should be
significant. The specific variable that we evaluated with respect to professional societies is whether
or not the use of a given genetic test has been incorporated into the society's recommended practice
guidelines. We established that by evaluating the guideline documents from the organizations'
websites.
Endorsement from breast cancer patient groups
While the majority of investment into research for diseases like cancer comes from the govern-
ment and private industry, philanthropic groups have also contributed significantly to the progress
that has been made in breast cancer care, prevention, and patient education and support. One
report estimated that disease foundations in the U.S. collectively invested about $90 million in
biotechnology companies to support the development of therapies that would directly benefit their
constituents [64], and tens of millions of dollars were also distributed through grants for investiga-
tors in academic and translational research. For example, the Breast Cancer Research Foundation
(BCRF) awarded over $34 million in research grants to 166 investigators in 2008 alone [65].
The biggest contributor of funds for breast cancer research and population health outside of the U.S.
government is the Susan G. Komen Breast Cancer Foundation, which allocates 85% of its funds to
research, education, and prevention, screening, and treatment programs. The Komen Foundation
is credited with pioneering the breast cancer awareness movement in 1982, when public dialog
about the disease was considered to be taboo [66]. While the Komen Foundation has cumulatively
provided over $400 million in research grants since 1982, direct patient support is also a key focus.
The foundation provides support for breast cancer patients, friends, and relatives through their
informational website, hundreds of regional affiliates, as well as through the funding of community-
based health and support programs, including the famous Komen Race for the Cure, a 5-kilometer
run and fitness walk that raises substantial funds for the foundation.
Foundations have significant power over the scientific research and policy agenda and can reach
large populations of patients through their outreach and support programs, so it logically follows
that many foundations implement patient advocacy programs. They have been involved in the
diffusion of several new practices developed by external organizations. For example, the Komen
Foundation published a 2006 whitepaper entitled, "Why Current Breast Pathology Practices Must
Be Evaluated," which called for stricter standards on the quality and accuracy of pathology diag-
nostics, improved training to develop breast cancer pathology specialists, and the implementation
of value-based reimbursement, among other calls to action [67]. This paper spurred a public de-
bate in the peer-reviewed literature and at conferences that brought the limitations of the current
pathology system under scrutiny, and also resulted in the creation of patient education resources
to increase awareness of variability in laboratory practices [68]. Advocacy groups like the Komen
Foundation have also been responsible for establishing and promoting population-wide screening
guidelines for patients, so we hypothesize that they can be shown to play an important role in the
diffusion of genetic tests for personalized medicine.
We selected a list of breast cancer foundations from CharityNavigator.org, a web-based listing
service that provides financial information and health ratings of over 5,400 American charity orga-
nizations. We searched for "breast cancer" to create a list of 26 organizations that conduct work in
that disease area. From there, we focused on the top five foundations as determined by 2007 or 2008
revenues, and further filtered to the three that provide comprehensive information, educational re-
sources, patient advocacy, and support for patients on their websites (see Table 6). For those three
foundations, we evaluated the level of explicit or implicit endorsement of each test by searching the
organizations' websites. A test was labeled as having explicit endorsement if the foundation had
published a formal statement encouraging the use of the test or encouraging patients to ask their
physicians about the test. Implicit endorsement denoted the mention of the test in portions of the
website where the foundation did not itself commission the authorship of the content (e.g. patient
message boards, external news stories, etc.).
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Table 6: List of breast cancer foundations used in this study
2008 revenues 2007 revenues
Susan B. Komen Foundation - $274,875,945
Breast Cancer Network of Strength - $10,662,657
National Breast Cancer Foundation $7,236,422 $6,205,000
Test scorecards
To summarize the findings across these dependent and independent variables, we used the "Test
Scorecard" in Table 7 to evaluate each genetic test.
Table 7: Sample Test Scorecard
Attributes [TEST NAME] NOTES
Clinical adoption
# of assays in 2007 ##,###





Strength of IP Strong-Medium-Weak
# of patents ##
U.S. protection Y-N
ex-U.S. protection Y-N
Clinical validity & utility
Clinical validity studies ##
Clinical utility studies ##








Breast Cancer Network of Strength
Explicit Y--N
Implicit Y-N
National Breast Cancer Foundation, Inc.
Explicit Y--N
Implicit Y-N
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Results
The findings from our analyses of each of the four tests are described below, followed by an aggregate
analysis of the independent variables and their correlation with clinical adoption. The full scorecard
for each test is included in Appendix B.
Test Scorecards
Myriad Genetics - BRACAnalysis
Myriad Genetics, one of the two divisions into which the parent company Myriad split in late
2008, provides both targeted mutation testing (specific mutations and three-mutation panels for
individuals with Ashkenazi Jewish ancestry) and whole gene sequencing services for the BRCA1
and BRCA2 genes. According to information in press releases and investor filings on the company's
website, a woman will have an 82% chance of developing breast cancer in her lifetime if she receives
a positive result from this test. Therefore, the test can help determine whether an individual is a
candidate for preventative treatment, like prophylactic surgery (bilateral oophorectomy, bilateral
mastectomy) or preventative chemotherapy, and/or increased screening through mammography
and MRI [69] [70]. The data collected for this thesis encompass all three versions of the test, unless
otherwise noted.
Myriad holds numerous U.S., European, and Canadian patents for specific mutations in the BRCA1
and BRCA2 genes and proprietary methodologies for determining the sequences of those genes [71].
These patents became the source of much debate and controversy when, in the early 2000's, Myriad
enforced its intellectual property rights through cease-and-desist letters to several academic and
hospital laboratories performing BRCA1/2 mutation tests [72]. These patents have enabled Myriad
to dominate the BRCA1/2 susceptibility testing market ever since, and though it is beyond the scope
of this thesis to discuss the implications of this arrangement on society, the genetic testing industry,
and innovation in general, one can imagine the potential effects of a patent-driven monopoly on
innovation diffusion: it may limit test access to only those who can afford its high price (whether
out-of-pocket or through insurance), prevent more accurate and cheaper tests from being brought
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to market, and interfere with the general diffusion of a testing paradigm to the universe of patients
who might benefit from it [72]. Despite these potentially negative outcomes, Myriad's 2007 sales
of the BRACAnalysis were an estimated $122 million, which translates into roughly 39,231 tests
(see Appendix Al for calculations). This was the highest number of assays among the four
tests we analyzed. Furthermore, the company estimates that less than 5% of the population of
roughly 600,000 BRCA1/2 mutation carriers has been identified as of December 2008 [71] [73], so
the BRACAnalysis test may have yet to experience its full revenue potential.
The BRACAnalysis test can cost between $300 and $3,120, depending on which of the three options
is selected. CMS only provides reimbursement for individuals who can be classified as high risk
through clinical algorithms that evaluate an individual's personal medical history and the medical
histories of first- and second- degree relatives [74]. Myriad also provides reimbursement assistance
for individuals who lack insurance or have policies that do not cover the price of the test. Myriad
conducts all BRACAnaylsis assays in-house in their CLIA-certified laboratory, and the test has not
been submitted for FDA review.
In order to evaluate the strength of clinical evidence surrounding the test, we examined the available
clinical validity, clinical utility and cost-effectiveness data for BRCA1/2 genetic testing, which
included, in some instances, ancillary services like genetic counseling. The clinical validity is strong -
that is, specific mutations in BRCA1 and BRCA2 have been reliably shown to result in significantly
increased risk for the breast cancer phenotype. Clinical utility has not yet been convincingly
demonstrated, largely because utility studies rely on pre-existing knowledge of the prevalence of the
mutations in the population, and this knowledge with respect to BRCA1/2 mutations is currently
weak [75] [76] [77]. One health economic study was identified that showed the cost-effectiveness of
follow-on treatments for carriers of BRCA1/2 mutations, but the evidence in that area, like with
the other three tests we evaluated, has yet to be replicated and supported [78].
Based on an interview with a medical geneticist in a large academic medical center, we learned
that while the BRCA1/2 genetic testing procedure has been incorporated into both the NCCN and
ASCO professional guidelines, it is still not broadly used outside of major hospital systems, largely
due to the requirement to provide specialized genetic counseling to patients in order to determine
whether or not testing is needed. The American Board of Genetic Counseling website states that
only 2,035 board certified genetic counselors exist in the U.S., so community physicians may find
it difficult to refer their patients for specialized genetic counseling services given the dearth of
expertise in this country.
Patient awareness of this test is likely high, given that all three of the patient groups we analyzed
made both explicit and implicit mention of hereditary breast cancer genetic testing, and specifically
BRCA1/2 testing, on their websites. Interestingly, many patients will sign their posts with their
genetic marker statuses, including their BRCA1/2 mutation status, as seen in the example in
Figure 10. This may encourage others to seek BRCA testing so that they can associate themselves
with others in the forums.
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Figure 10: A patient's signature at the end of her message board posting that includes her BRCA1/2 and
ER/PR status
While we did not evaluate the role of other information sources that might influence patient choice,
it is clear that Myriad's substantial direct-to-consumer marketing efforts and numerous mentions
in the popular press may have increased awareness in the general public, therefore encouraging
individuals to seek testing if they thought they might be at high risk for hereditary breast or
ovarian cancer [79].
See Appendix B1 for the full Myriad BRACAnalysis scorecard.
Genomic Health - Oncotype DX
Oncotype DX, a product of the California-based company, Genomic Health, is a 21-gene expression
assay that uses RT-PCR to detect levels of gene transcripts (mRNA) in formalin-fixed paraffin-
embedded (FFPE) tissue samples from breast tumors. It is intended for use in the prediction of the
likelihood of distant cancer recurrence in women with newly diagnosed Stage I or II breast cancer,
who are lymph-node negative, ER-positive, and who will be treated with the drug tamoxifen. Based
on the results of the expression assay, a proprietary algorithm produces a Recurrence Score (RS)
that stratifies the patient into the Low Risk (less than 18), Intermediate Risk (18-31), or High Risk
(31-50) group. Patients who classify as High Risk are more likely to experience distant recurrence
and are therefore most likely to benefit from chemotherapy, while Low Risk patients will probably
not benefit and can avoid the unnecessary side effects of the treatment. Physicians may use their
judgment based on additional knowledge for patients in the Intermediate Risk category, but at
least two studies indicate that treatment with chemotherapy is effective in reducing their risk of
recurrence [80].
The test is delivered through Genomic Health's internal CLIA laboratory, and while the FDA has
sent a letter to the company to engage them in a dialog about the potential regulation of their test,
the Oncotype DX assay has not yet been submitted for review to the FDA. One of the perceived
operational benefits of this test is its ability to use formalin-fixed, paraffin-embedded tissue samples,
which is the standard method for storing tissue samples after biopsying a patient. By leveraging a
standard procedure and not having to change the clinical workflow to facilitate sample preparation,
Genomic Health was able to both analyze historical samples of breast cancer tissues from patients
whose outcomes were known for the purposes of validation, as well as introduce its product into
the clinical setting without requiring any significant changes in behavior on the part of the surgical
physicians, pathologists or patients [81]. Our interviewees stated that this gives Oncotype DX an
edge relative to its most direct competitor, MammaPrint, which we discuss in the next section.
The level of clinical adoption of Oncotype DX was the second highest in our test set, after Myriad's
BRACAnalysis. The test is reimbursement through CMS at a rate of $3,650 [81], and the com-
pany provides reimbursement assistance for patients who do not have coverage under their plans.
According to the company's 2007 annual report, 24,500 assays were delivered that year, which was
a 69% increase from the previous year [82]. The test has only been on the market since 2004, but
Genomic Health has an opportunity to address at least 64,000 additional patients per year based
on current prevalence estimates [81], so Oncotype DX may be early on in its diffusion through the
medical establishment.
In terms of intellectual property, Genomic Health has relatively weak patent protection over its
Oncotype DX product. In 2006, the company announced the issuance of two patents (7,056,674
and 7,081,340) that covered up to 14 genes and their utility in breast cancer prognosis testing.
At least 4 others (11,102,228, 10,886,501, 10,963,286, 10,035,814) that cover applications of gene
expression profiling for predicting chemotherapy response, quantitative PCR methods, RT-PCR
methods, and an information system and methods for genomic profiling, respectively, have been
submitted, but not yet assigned. No European patents covering Oncotype DX were identified.
The test is backed by strong clinical validation data, while definitive clinical utility and cost-effective
data are still lacking. Oncotype DX was clinically validated through multiple retrospective studies,
namely a series of studies sponsored by the NBASP, to show that their gene expression algorithm
correctly classifies individuals into high, intermediate, and low risk categories by clinical measures
[83]. Its clinical utility is being evaluated prospectively through the Trial Assigning IndividuaLized
Options for Treatment (Rx) (TAILORx), which began in 2006 [83]. One recent health economic
study concluded that the costs associated with administration of adjuvant chemotherapy in a 100-
patient cohort could be reduced by 46% (from $1.63 million to $880,000) through the use of the
test, while the costs of follow-up and treatment in case of recurrence would only increase by 8%
(from $2.69 million to $2.90 million). After factoring in the cost of the test, the net savings per
patient was calculated to be about $2,000 [84]. While this provides one piece of compelling evidence
for the test's cost-effectiveness, larger and more comprehensive replication studies are still needed
to verify and validate the results.
The third party organizations we examined endorse Oncotype DX almost universally. ASCO and
- ------ ------------- -L I I L__ .,.
NCCN have included the use of Oncotype DX in their 2009 professional guidelines. Of the three
breast cancer foundations we studied, only the National Breast Cancer Foundation did not mention
Oncotype DX explicitly on its website, but the websites of all three foundations included implicit
references to the test through their patient message boards and external press releases. Much of
the discussion on the message boards was between patients who were giving each other advice
on obtaining insurance coverage for the test, asking their physicians about the test, and generally
encouraging each other to get tested. Several patients also expressed frustration that their physician
did not order the test, and respondents suggested that perhaps their oncologists did not know
about Oncotype DX, and that the patient should educate herself through web-based literature
before asking her oncologist about it [85]. Without accounting for the potentially low conversion
rates when patients push physicians to order a test, this patient forum activity demonstrates the
momentum that a product can gain through patient-driven peer education and word-of-mouth
marketing.
See Appendix B2 for the full Genomic Health Oncotype DX scorecard.
Agendia - MammaPrint
Agendia developed its 70-gene prognostic test, MammaPrint, using a customized microarray chip
designed by Agilent. The test has been available in the Netherlands since 2005, and it received
FDA 'de novo 510K' approval for marketing in the U.S. in 2007. It is indicated for patients who
are younger than 61 years of age and have been diagnosed with either Stage I or II invasive breast
cancer that is lymph node negative and either ER-positive or ER-negative. The test has been shown
to reliably classify patients into 'poor' and 'good' prognosis categories based on 10-year survival
rates [86], and the physician report provides a similar classification of the tumor into 'high' and
'low' risk profiles.
While MammaPrint is already in wide use in the Dutch medical system, it has not yet gained
wide adoption in the U.S. However, according to the company's website, it recently raised $34
million in financing in order to make an aggressive entry into the U.S. market. Physicians who
were interviewed stated that MammaPrint may turn out to have wider applicability than Oncotype
DX given its broader set of genes (70 versus Oncotype DX's 21) and its indication for both ER-
positive and ER-negative tumors (Oncotype DX is only indicated for ER-positive tumors), but they
also criticized the test due to its requirement for fresh frozen tissue, as opposed to formalin-fixed,
paraffin-embedded tissue, which may be operationally difficult to provide through the standard
biopsy workflow.
The price of the test is roughly $4,200 (the highest of the four tests we analyzed), and because the
test is not in wide use in the U.S., it understandably does not have reimbursement through CMS
as of yet. Clinical validity of the assay was shown through at least 4 studies, which verified the
concordance of patient clinical status with the classification provided through the test [83]. The
MINDACT trial is currently evaluating the clinical utility of MammaPrint assay prospectively, in
comparison with the standard of care (the Adjuvant! Online prognosis tool). One health economic
study showed that MammaPrint yields lower total costs for patients who may be indicated for
adjuvant chemotherapy ($29,754 vs. $32,636) [87], though the cost-effectiveness argument for this
test, like all others in this study, is still weak [83].
The MammaPrint test has not been incorporated into the practice guidelines of either the NCCN
or ASCO, though both NCCN and ASCO acknowledge the test as a potentially useful tool and are
awaiting additional clinical data to conduct reviews similar to those they completed for Oncotype
DX. The test received explicit endorsement from the Breast Cancer Network of Strength through a
single descriptive page dedicated to the test (though it did not formally encourage patients to ask
their physicians about testing). An implicit mention of the test was made on the message boards
and external news articles linked from the Susan G. Komen website. None of the patients who
posted messages that referred to MammaPrint had actually received the test, but many individuals
were very curious about the test relative to Oncotype DX, and some even implied that the larger
number of genes relative to Oncotype DX (70 versus 21) might make it a better test to receive [88].
See Appendix B3 for the full Agendia MammaPrint scorecard.
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Roche - AmpliChip CYP450
Roche combined its proprietary PCR technology with Affymetrix's proprietary microarray chip
technology to create the AmpliChip CYP450 test. This assay can detect 29 alleles of the CYP2D6
gene and 2 polymorphisms in the CYP2DC29 gene in order to determine an individual's CYP450
phenotype, which informs the rate at which he or she metabolizes certain drugs [89][90]. About
7% of Caucasians are believed to be poor metabolizers, which may result in a higher risk of drug-
related toxicity due to overdose [91]. The phenotypes associated with various genotypes of CYP2D6
are listed in Table 8, along with the predicted metabolic outcomes. CYP2D6 genotypes may be
used for breast cancer patients to predict response to tamoxifen, a commonly prescribed endocrine
drug for patients whose tumors are ER- or PR-positive. The CYP450 test is also applicable to
many other disease areas, given that the cytochrome P450 family of enzymes is responsible for
metabolizing about 75% of all drugs [92].
Table 8: CYP2D6 gene alleles and associated phenotypes
Phenotype Alleles Predicted outcome with tamoxifen
Poor metabolizer (PM) *3, *4, *5, *6, *4 x n, *20 Low efficacy/increased toxicity
Intermediate metabolizer (IM) *9, *10, *17, *41 Intermediate efficacy/potential toxicity
Extensive metabolizer (EM) *1, *2, *35 Good efficacy/less potential toxicity
Ultrarapid metabolizer (UM) *1 x n, *2 x n Superior efficacy/rare toxicity
Note: "[number] x n" indicates the existence of multiple copies of a given allele (copy number variation)
Source: Ramon y Cajal T, Altes A, Pare L, del Rio E, Alonso C, Barnadas A, Baiget M. "Impact of CYP2D6
polymorphisms in tamoxifen adjuvant breast cancer treatment." Breast Cancer Treatment Research. 2009; E-pub
ahead of print.
Roche Diagnostics received FDA approval for its AmpliChip CYP450 in vitro diagnostic assay in
2005 and experienced what analysts called "lackluster results" during its first 3 years on the market
[93]. This presumed slow uptake was confirmed by our clinical adoption measurements, which
showed that only about 10,500 tests were performed in 2007 (see Appendix A2 for calculations),
and that reimbursement for the test was not guaranteed through CMS. Some explanations that
have been cited in the press for slow uptake of this test are as follows:
* High cost of lab equipment (an estimated $219,000 for the core machine, plus $55,000 for
each fluid station)
* Lack of comprehensive reimbursement
* Low throughput of machines (only 4 samples can be run in an 8-hour period, unless additional
fluid stations are purchased; configuration cannot be further optimized to increase throughput,
since the kit is FDA approved for its specific out-of-the-box configuration)
* Need to perform both the CYP2D6 and CYP2DC19 gene tests at one time, which could
produce undesired confounding results.
Reports in the press stated a price of around $1,000 for the assay, and we further confirmed the
validity of that number by estimating the cost of the test based on CPT codes from LabCorp's
website. Using the Massachusetts rates for CPT reimbursement [94], we calculated a cost of $564.07
for the test, including the reported cost of the chip itself (see Appendix A3 for calculations). A
price of $1,000 represents about a 45% margin on the test, which is reasonable for a genetic test
based on the reported testing margins of other comparable companies [95].
The clinical validity of the genotypes of the CYP450 pathway of enzymes and their correlation to
metabolic phenotype has been shown through numerous studies [96]. Specifically for tamoxifen
metabolism, CYP2D6 genotypes have shown valid correlation with the level of active tamoxifen
metabolites in the blood plasma, though the evidence for clinical utility as measured by outcomes
has not yet been shown prospectively [97]. One health economic study showed evidence of the cost-
effectiveness of this test, though it only focused on one CYP2D6 allele, and the results were not
thought to be generalizable to non-Caucasian populations [98][99]. Therefore, the overall strength
of the clinical evidence around this test is relatively weak.
The CYP2D6 genotype test has not yet been integrated into professional guidelines for NCCN
or ASCO, nor has it been mentioned in any of the patient group websites explicitly, though it
did receive mentions in message boards on the Komen Foundation and Breast Cancer Network
of Strength websites and in external news articles on the Komen Foundation website. Expert
interviewees confirmed that the AmpliChip test is very early in its lifecycle and therefore is used
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very rarely, if ever, even in their large academic hospital settings. This claim is supported by the
number of assays that we calculated for the test, which is the lowest of the four tests, and may
account for usage in other disease areas.
See Appendix B4 for the full Roche AmpliChip CYP450 scorecard.
Overall findings on clinical adoption
We stratified the four tests into two tiers based on their clinical adoption measures of CMS re-
imbursement and number of assays completed in 2007. Myriad's BRACAnalysis and Oncotype
DX achieved higher clinical adoption than MammaPrint and AmpliChip CYP450, having obtained
standardized reimbursement through CMS and completed over 20,000 assays in 2007, versus the
less than 15,000 completed by the latter two tests. We will refer to these tiers as "high" and
"low" for this analysis (see Table 9), though those are clearly relative measures and do not denote
absolute adoption, or lack thereof.
Table 9: Stratification of tests into 'high' and 'low' clinical adoption tiers
High Low
Myriad BRACAnalysis Agendia MammaPrint
Genomic Health Oncotype Roche AmpliChip
DX CYP450
While both tests in the high tier receive reimbursement through CMS, Myriad's BRACAnalysis
test achieved the highest clinical adoption of all based on number of assays performed. Roche's
AmpliChip CYP450 has the lowest clinical adoption based on the same measure.
Variables that correlate with clinical adoption
Four variables correlated with high and low adoption in our study: 1) regulatory status, 2) pro-
fessional society endorsement, 3) explicit endorsement by at least 2 patient groups, and 4) implicit
endorsement by all 3 patient groups. The high tier tests were both commercialized through the
CLIA pathway, while both of the low tier tests had received some sort of FDA approval (de novo
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510K or regular 510K). Both tests in the high tier were recommended in the NCCN and ASCO
practice guidelines, while neither of the low tier tests had endorsement from either society. Finally,
BRACAnalysis and Oncotype DX were both explicitly mentioned by at least two patient groups
(the National Breast Cancer Foundation mentioned BRACAnalysis explicitly, but not Oncotype
DX). Both high tier tests were mentioned implicitly in message boards on the websites of all three
foundations, while the low tier tests were mentioned implicitly by only one or two foundations.
Other variables
The remaining variables were not correlated with clinical adoption for these four tests. All four tests
were protected by intellectual property, and the test with the weakest patent portfolio (Oncotype
DX) actually showed high clinical adoption, demonstrating that intellectual property may not be
a requirement for diffusion at the level of an individual genetic test. In fact, Oncotype DX was
the only test that exhibited weak intellectual property; the others all had strong patent protection.
No direct correlation was observed with price - the tests with the highest and lowest prices ended
up in the low tier for clinical adoption. All four tests were backed by relatively strong evidence of
clinical validity, while none of them had strong evidence of clinical utility or cost-effectiveness.
Discussion
Our goal was to evaluate the utility of the inclusion of specific attributes of genetic tests, endorse-
ments from medical professional societies, and endorsements by patient groups in frameworks for
analyzing the diffusion of medical innovations in personalized medicine. We accomplished that by
studying four breast cancer genetic tests that are currently in clinical use with varying levels of
adoption. The results show that the dependent variables we chose for measuring clinical adoption
seem to be reliable, as confirmed through interviews with "early innovator" physicians who make
frequent use of genetic tests for breast cancer care. The BRACAnalysis and Oncotype DX tests had
the highest level of clinical adoption, while the MammaPrint and AmpliChip assays had the low-
est, and these results are concordant with subjective and anecdotal information gathered through
physician interviews, news reports, and literature searches.
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Utility of this knowledge for research and commercial applications
The independent variables exhibited varying levels of strength in terms of their correlation with
clinical adoption. Of the four variables that correlated with high adoption, three reflected the
endorsements of physician and patient groups, which have not yet been evaluated explicitly in past
medical innovation diffusion studies. Our analysis shows that third-party organizations may play
a key role in facilitating the diffusion of novel medical products in the personalized medicine era,
and we surmise that the role of patient groups, in particular, may have been overlooked in the
past by stakeholders who are involved in the development and commercialization of genetic tests.
Knowledge of the potential importance of the novel associations that we elucidated in this thesis
(namely, the correlation between endorsement from professional societies and patient groups with
clinical adoption) can be utilized in the context of the commercialization of new genetic tests. We
hope that companies, investors, payers, patients, and other parties with an interest in the diffusion
of innovations in health care use the variables that we highlight in this study to generate effective
strategies for developing new personalized medicine products.
Limitations and biases
Our study had several limitations and potential biases that may restrict the broader applicability
of its results. Firstly, the size of the data set was relatively small, and any conclusions we draw
from this study may not be generalizable to a larger universe of genetic tests, or to tests in disease
areas other than breast cancer. The data set also itself exhibits inherent variance with respect
to application area (i.e. susceptibility testing vs. prognosis vs. pharmacogenomics), and because
each application area has its own unique clinical characteristics, patient populations, and contex-
tual drivers, any patterns or trends that we observed based on our analysis may be the result of
idiosyncratic bias.
Another potential limitation of our measurement of clinical adoption is the fact that each of the
four tests may be at a different point in its diffusion lifecycle, so a direct comparison between
specific variables may be uninformative. For example, the number of assays performed for a given
test may be a less optimal proxy for adoption than a measure that accounts for the percentage of
the potential market that has been penetrated over the length of time the product has been on the
market. In the pharmaceutical industry, standard curves can be drawn to model the revenues from
a drug between its launch and its patent expiration based on historical sales data for hundreds of
compounds. While these curves can be derived for individual value-based genetic tests, there are
too few examples of such products that have been on the market for a sufficient period of time
to draw representative curves that could be used for this study. In terms of the size of the target
patient populations, there may be significant differences between the tests for which we did not
account. For example, the potential patient population for BRACAnalysis may have very little
overlap with that of Oncotype DX, so while BRACAnalysis saw the highest number of assays in
2007, it may turn out that the company has hit a plateau in terms of sales of that product because
they have penetrated the full market of high-risk individuals, while Oncotype DX may have only
diffused through a small percent of its overall market, thus having more growth potential. An
extension of this study might derive a metric that normalizes for market penetration and time scale
to address these issues.
Intellectual property was evaluated as a direct independent variable in this study, but we recognize
that the value of patents may not manifest itself in the form of the clinical adoption of a single test.
Our conclusion that intellectual property is not correlated with clinical adoption of genetic tests
does not account for the corporate-level value of patents; patents may create secondary benefits
in the form of economies of scope through the ability to develop multiple tests from one patented
technology platform, the freedom to operate within a given disease or application area, and ability to
license bundles of IP for additional, profitable revenue. Intellectual property may also increase the
enterprise value of a firm and potentially contribute to the ability to attract investors, acquirers
or partners. Therefore, companies looking to develop and commercialize these tests should not
discount the innate value of a strong intellectual property portfolio based on our results.
Confounding bias may also exist in our observation of the correlation between clinical adoption and
the incorporation of a genetic test into the practice guidelines of major medical societies, since this
incorporation may itself be driven by the same variables that drive clinical adoption. A key point
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that emphasizes this potential bias is that medical professional societies typically state that they
review clinical validity and utility data when reviewing practices for inclusion in their guidelines;
for example, ASCO states that it selects topics for inclusion based on their "significance of clinical
or economic importance." Thus, inclusion in practice guidelines may also hold merit as a dependent
variable in subsequent studies.
Future research on the diffusion of genetic tests
More rigorous research is needed to accurately describe the diffusion curves and adoption behaviors
for novel innovations in personalized medicine. However, this thesis allows us to generate informed
hypotheses about several factors that may contribute to the adoption of one type of medical inno-
vation involved in personalized medicine: the genetic test. The genetic testing market is predicted
to grow exponentially from $390 million in 2009 to nearly $2 billion in 2014 for cancer alone [7],
and novel genomic discoveries in other disease areas will likely to contribute to an expansion of the
universe of genetic tests that can aid in the widespread implementation of personalized medicine.
As the use of these novel innovations diffuses through the medical establishment and relevant pa-
tient populations, it will be important to acknowledge the role of third-parties that have not been
considered in traditional diffusion models, including patient groups and medical professional soci-
eties. In particular, the emerging trend of "consumer-driven health care" points to a need to better
understand and characterize the role of the patient in driving her own medical care [101], and
patient groups can certainly play the role of the intermediary in educating their constituents about
new products, practices, and research, and advocating for awareness and access to the relevant
areas of the complex health care system.
Future investigations may focus on the following results and intuitions that we gained from our
study:
* Patient groups can facilitate the diffusion of medical innovations by mediating knowledge ex-
change between the medical community and patient populations. This may be a yet untapped
mechanism for driving the diffusion of medical innovations.
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* The uncertainty in the regulatory environment for genetic tests has resulted in the ability for
companies to "fast-track" their products to market, but clinical validity and utility are still
important in gaining true adoption by both physicians and payers.
* Several examples of value-based genetic testing exist, but until fundamental changes to the
reimbursement system are made to more broadly accommodate value-based payments, com-
panies may find it difficult to gain reimbursement (and clinical adoption) without investing
significant time in working with payers to prove the value of their products.
Subsequent studies might also look at a larger number of tests within a given application area -
for example, ten breast cancer tests that focus on prognostic testing - or even broaden the disease
focus - for example, ten prognostic tests across all cancer indications - to introduce more statistical
rigor to a similar analysis. Several variables were not analyzed as part of our study that may also
be important to the evaluation of clinical adoption of genetic tests. These include, but are not
limited, to the following:
* Cumulative amount of marketing/lobbying spend. As highlighted by early diffusion
studies, marketing (both direct-to-consumer and direct-to-physician) may play a key role in
raising awareness of a new medical product or practice, and therefore may prove to be a
significant independent variable in the evaluation of clinical adoption.
* Company financing history and cash position. A company's ability to invest in clinical
studies, product development, marketing, and human resources may also directly affect its
product sales.
* Level of unmet medical need in the patient population. A patient population who
has no existing medical options may be quicker to drive adoption of a new medical product
than one in which a plethora of options exist.
* Different characteristics of the prescribing physicians by specialty (e.g. oncolo-
gists versus geneticists). Because cancer care for a given patient involves so many health
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care workers across multiple disciplines, it is worth examining the different characteristics
(i.e. the level of "innovativeness") across specialty areas to identify any significant deviations
or similarities.
Each one of these variables could constitute a separate study, and we hope that future research
will address the current lack of structured knowledge in these areas with a specific focus on genetic
tests and other such medical innovations for personalized medicine.




Appendix Al: BRACAnalysis estimated number of assays performed per year
Table 10: BRA CAnalysis estimated number of assays performed per year
Year Total test revenues1  Number of assays2  Growth rate3
2007 $122,400,000 39,231 1.44
2006 $85,000,000 27,244 1.42
2005 $60,000,000 19,231 1.71
2004 $35,000,000 11,218 1.17
2003 $30,000,000 9,615 -
1. Years 2003-2006 derived from AllianceBernstein report [102]; year 2007 calculated using
growth rates
2. Calculated using test price of $3,120
3. Years 2004-2006 derived from data in AllianceBerstein report [102]; year 2007 taken from
company's 2008 annual report [71]
Appendix A2: AmpliChip estimated number of assays performed per year
Table 11: AmpliChip estimated number of assays performed per year
Year Total EU Growth ratel AmpliChip AmpliChip Number of
revenues1  share 2  revenues 3  assays4
2007 $72,200,000 11.7% 14.6% $10,541,200 10,541
2006 $64,600,000 13.2% 14.6% $9,431,600 9,432
2005 $57,100,000 14.6% $8,336,600 8,337
1. From actual and estimated value in 2006 Frost & Sullivan report [103].
2. From actual and estimated value in 2006 Frost & Sullivan report; Roche AmpliChip share
was reported to be "stable", so we kept the percentage constant over the three year period
[103].
3. Calculated by multiplying "Total EU revenues" and "AmpliChip share".
4. Calculated using test price of $1,000, based on reported assay and interpretation prices in the
literature.
This estimation only includes the European market. However, based on reports that AmpliChip
sales have been low in the U.S., this estimate is likely sufficient for both regions.
Also, the AmpliChip test is not exclusively used for breast cancer patients, but the values cal-
culated here represent sales across all disease areas.
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Appendix A3: AmpliChip cost estimation
Table 12: Estimated cost of performing the AmpliChip CYP450 assay
CPT Description MA rate # of Total
Code repeats
83891 Molecular diagnostics; isolation or extraction $5.85 1 $5.85
of highly purified nucleic acid, each nucleic
acid type (ie, DNA or RNA)
83892 Molecular diagnostics; enzymatic digestion, $5.85 1 $5.85
each enzyme treatment
83900 Molecular diagnostics; amplification, target, $12.75 1 $12.75
multiplex, first 2 nucleic acid sequences
83901 Molecular diagnostics; amplification, target, $6.37 2 $12.74
multiplex, each additional nucleic acid
sequence beyond 2
83912 Molecular diagnostics; interpretation and $5.85 1 $5.85
report
83914 Mutation identification by enzymatic ligation $6.37 19 $121.03
or primer extension, single segment, each
segment (eg, oligonucleotide ligation assay
[OLA], single base chain extension [SBCE],
or allele-specific primer extension [ASPE])
Cost of procedures $164.07
Cost of chip $400.00
TOTAL $564.07







Massachusetts rates for CPT reimbursement were used to calculate the costs of the procedure [104].
Appendix B: Test Scorecards
Appendix BI: Myriad BRACAnalysis Scorecard
Table 13: BRACAnalysis Test Scorecard
Attributes BRACAnalysis NOTES
Clinical adoption
# of assays in 2007 39,231





Strength of IP Strong
# of patents 22
U.S. protection Y
ex-U.S. protection Y
Clinical validity & utility
Clinical validity studies At least 22 studies to show high
penetrance of BRCA1/2 mutations;
strong evidence
Clinical utility studies 16 observational studies on BRCA1/2 Utility depends on penetrance of
mutation carriers and outcomes; weak BRCA1/2 mutations; not enough
evidence knowledge of penetrance exists to truly
assess utility of interventions
Health economic studies At least 1 that compares cost
effectiveness of preventative strategies
after BRCA1/2 testing
Professional guidelines
NCCN Y Only for high-risk individuals
ASCO Y Only for high-risk individuals
Mentions by foundations
Susan B. Komen
Explicit Y Recommendation to ask doctor if at
risk for BRCA1/2 mutations [105]
Implicit Y Mentioned in at least one personal pa-
tient testimonial [106]
Breast Cancer Network of Strength
Explicit Y Guidelines on pros and cons of genetic
testing for BRCA mutations [107
Implicit Y Mentioned in message boards
National Breast Cancer Foundation, Inc.
Explicit Y Addressed to dispel myths about pre-
vention [108]
Implicit Y Mentioned in message boards
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Appendix B2: Oncotype DX Scorecard
Table 14: Oncotype DX Test Scorecard
Attributes Oncotype DX NOTES
# of assays in 2007 24,500




Strength of IP Weak
# of patents 2
U.S. protection Y
ex-U.S. protection N
Clinical validity & utility
Clinical validity studies 5 studies; strong evidence
Clinical utility studies 5 retrospective studies; weak evidence 1 ongoing prospective trial (TAILORx)
Health economic studies 2 studies; weak evidence
Professional guidelines
NCCN Y For LN-negative, ER-positive patients
prescribed to take tamoxifen
ASCO Y For LN-negative, ER-positive patients
prescribed to take tamoxifen
Mentions by foundations
Susan B. Komen
Explicit Y Mentioned in positive light in
foundation-written article [109]
Implicit Y Mentioned in message board
Breast Cancer Network of Strength
Explicit Y Dedicated page for explaining the test
[110]
Implicit Y Mentioned in message boards
National Breast Cancer Foundation, Inc.
Explicit N
Implicit Y Mentioned in message board
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Appendix B3: MammaPrint Scorecard
Table 15: Oncotype DX Test Scorecard
Attributes MammaPrint NOTES
# of assays in 2007 12,000
Reimbursement by CMS N
Year introduced 2007
Regulatory status FDA 'de novo 510K' First IVDMIA to be cleared by FDA
Price $4,200
IP
Strength of IP Strong




Clinical validity & utility
Clinical validity studies 4 studies; strong evidence
Clinical utility studies 0 1 ongoing prospective trial (MIN-
DACT)
Health economic studies 1 study; weak evidence Study showed poorer quality-adjusted







Implicit Y Mentioned in forums and external
news articles
Breast Cancer Network of Strength
Explicit Y Dedicated page for explaining the test
[111]
Implicit N
National Breast Cancer Foundation, Inc.
Explicit N
Implicit N
Appendix B4: AmpliChip CYP450 Scorecard
Table 16: Oncotype DX Test Scorecard
Attributes AmpliChip CYP450 NOTES
# of assays in 2007 10,541
Reimbursement by CMS N
Year introduced 2005
Regulatory status FDA 510K First FDA-cleared microarray
Price $1,000
IP..
Strength of IP Strong




Clinical validity & utility
Clinical validity studies At least 6 studies; variable evidence Some evidence of correlation between
CYP2D6 genotype and plasma level
of active metabolites of tamoxifen,
though lots of overlap between groups;
still no strong evidence for correlation
between endoxifen levels and efficacy
of drug
Clinical utility studies 0







Implicit Y Mentioned in message boards and ex-
ternal news articles; shows abstract of
funded research dealing with role of
CYP2D6 in drug response
Breast Cancer Network of Strength
Explicit N
Implicit Y Mentioned in message boards
National Breast Cancer Foundation, Inc.
Explicit N
Implicit N
.. . .... . ......
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